New Therapeutic Target in Glioblastoma: FGL2

​ In an immune regulatory protein that promotes the progression of glioblastoma multiforme (GBM) by suppressing the immune system, researchers at the University of Texas MD Anderson Cancer Center have found a potential therapeutic target. Until now, little research has been done about the role of immune-associated genes in the progression of brain tumors. "Classical wisdom is that brain tumor progression is linked to oncogene activation and tumor suppressor gene inactivation; however, genetic an...
Continue reading

Grouped MicroRNAs Fight Glioblastomas

MicroRNAs—strings of nucleotides that bind to and destroy messenger RNA to prevent the production of certain proteins—have been discovered to play an important role in cancer and other diseases. However, in previous preclinical trials, microRNA cancer treatments lacked efficacy. In recent developments, scientists at Brigham and Women's Hospital and Harvard Medical School grouped micro-RNA molecules together, encoding them in a small, artificial gene, and then infiltrated cancer cells to overprod...
Continue reading

Shrinking Medulloblastomas Without Chemotherapy

Chemotherapy is an effective treatment for many cancers; however, the side effects can have huge consequences, especially on pediatric patients, who are still growing. In particular, children treated for medulloblastoma—the most common malignant pediatric brain tumor—have devastating lifelong side effects from chemotherapy. Less harmful treatments are needed. In a new study published in Nature Communications , scientists have discovered that inhibiting an epigenetic modifier protein called lysin...
Continue reading

A Way to Avoid Glioblastoma Invasion

Researchers' discovery that forces enhancing fluid flow within a glioblastoma's interstitial spaces can increase the cancer's invasion of surrounding tissue has critical implications for a new drug delivery technique. However, the investigators have also found a solution to this problem. The most common form of brain cancer, glioblastoma is also the most malignant. Because it is characterized by invasion into the surrounding brain tissue, it is highly difficult to treat and invariably relapses. ...
Continue reading

Implementing Molecular Profiling at Initial Diagnosis for Pediatric Brain Tumor Patients With James M. Olson, MD, PhD

James M. Olson, MD, PhD

​Brain and spinal cord tumors are the second most common cancers in children, accounting for 1 out of 4 childhood cancers. Despite intensive treatment, children with histologically diagnosed high-risk medulloblastoma, supratentorial primitive neuroectodermal tumor of the central nervous system (CNS-PNET), and pineoblastoma (PBL) continue to have suboptimal outcomes. James M. Olson, MD, PhD, Professor of Pediatric Hematology/Oncology at University of Washington School of Medicine, and colleagues found that molecular profiling of patients with CNS-PNET/PBL revealed a significant proportion of patients were initially misdiagnosed and consequently overtreated and that other patients have a better prognosis than previously realized. i3 Health spoke with Dr. Olson about these findings and their implications for pediatric brain tumor practice.

Continue reading

© Copyright 2019 i3 Health. All rights reserved.